公司资料
Grifols 股价、新闻与催化剂
- 股票代码:
- GRFS
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
7.40 USD (0.00%)
收盘价
最后更新: 2026年9月17日
5.19B USD
市值
股价为何变动
截至 2026年9月17日，GRFS 股价变化不大，收于 $7.40。当前新闻监测窗口内未发现新的同公司新闻。
公司概览
业务概览
Grifols is a plasma-therapeutics company with a major business in immunoglobulins, plasma-derived medicines, and diagnostics.
所在地与行业分类
Headquartered in Spain and listed in the United States as an ADR, Grifols has a global plasma and diagnostics footprint.
商业模式特征
The company depends on plasma collection, manufacturing execution, and steady demand for specialty biologics.
生物医药行业定位
Grifols sits in a unique biologics niche where supply chain, pricing, and plasma collection trends matter as much as clinical catalysts.
未来催化剂
- Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
近期新闻
新闻标题由机器翻译，详情为英文原文。
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。